Research

Hormonal

GLP-1/GIP receptor co-agonists may provide cardiovascular protection and slow the decline of kidney function in individuals with type 2 diabetes.

GLP-1/GIP receptor co-agonists may be considered for patients with type 2 diabetes at risk for cardiovascular and kidney issues.

GoodQualifiesmedium confidence
A post hoc analysis suggested tirzepatide slows the decline of kidney function in T2D.
Ronald Goldenberg et al. · Current Opinion in Cardiology · 2023

Why this rating

Based on post hoc analysis of clinical data.

Source

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data

Ronald Goldenberg et al. · Current Opinion in Cardiology · 2023

DOI 10.1097/hco.0000000000001084

reviewCited 12×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →